Does the media favor INO or MRNA?

In the previous week, Moderna had 25 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 32 mentions for Moderna and 7 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.75 beat Moderna's score of 0.55 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 11 Very Positive mention(s) 10 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Is INO or ZURA more profitable?

Zura Bio's return on equity of -56.13% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% Zura Bio N/A -56.13% -50.15%

Does the media prefer INO or ZURA?

In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.28 beat Inovio Pharmaceuticals' score of 0.75 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is KYTX or INO more profitable?

Kyverna Therapeutics' return on equity of -81.92% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.92% -63.74% Inovio Pharmaceuticals N/A -669.94% -73.97%

Does the media favor KYTX or INO?

In the previous week, Inovio Pharmaceuticals had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.67 beat Inovio Pharmaceuticals' score of 0.75 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Inovio Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ENTX or INO more profitable?

Entera Bio's return on equity of -147.19% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Inovio Pharmaceuticals N/A -669.94% -73.97%

Does the media prefer PRTA or INO?

In the previous week, Inovio Pharmaceuticals had 5 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 2 mentions for Prothena. Prothena's average media sentiment score of 1.27 beat Inovio Pharmaceuticals' score of 0.75 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inovio Pharmaceuticals (INO) Competitors

$1.25 -0.03 (-2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 -0.04 (-3.60%)

As of 07:09 PM Eastern

Compare

INO vs. MRNA, ZURA, KYTX, ENTX, and PRTA

Should you buy Inovio Pharmaceuticals stock or one of its competitors? Inovio Pharmaceuticals's main competitors and comparable companies include Moderna (MRNA), Zura Bio (ZURA), Kyverna Therapeutics (KYTX), Entera Bio (ENTX), and Prothena (PRTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Inovio Pharmaceuticals compare to Moderna?

Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

In the previous week, Moderna had 25 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 32 mentions for Moderna and 7 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.75 beat Moderna's score of 0.55 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	11 Very Positive mention(s)	10 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Moderna	-141.43%	-28.30%	-19.39%

Inovio Pharmaceuticals currently has a consensus target price of $3.17, suggesting a potential upside of 153.33%. Moderna has a consensus target price of $76.72, suggesting a potential downside of 46.71%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	2,154.17	-$84.95M	-$0.91	N/A
Moderna	$1.94B	29.57	-$2.82B	-$7.99	N/A

Inovio Pharmaceuticals has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Moderna has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Summary

Inovio Pharmaceuticals beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Zura Bio?

Inovio Pharmaceuticals (NASDAQ:INO) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Inovio Pharmaceuticals has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

Inovio Pharmaceuticals presently has a consensus price target of $3.17, suggesting a potential upside of 153.33%. Zura Bio has a consensus price target of $17.00, suggesting a potential upside of 226.30%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts plainly believe Zura Bio is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Inovio Pharmaceuticals has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	2,154.17	-$84.95M	-$0.91	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

Zura Bio's return on equity of -56.13% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Zura Bio	N/A	-56.13%	-50.15%

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 12.4% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.28 beat Inovio Pharmaceuticals' score of 0.75 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zura Bio beats Inovio Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Kyverna Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 313.22%. Inovio Pharmaceuticals has a consensus price target of $3.17, suggesting a potential upside of 153.33%. Given Kyverna Therapeutics' higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Inovio Pharmaceuticals has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Inovio Pharmaceuticals	$60K	2,154.17	-$84.95M	-$0.91	N/A

Kyverna Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Inovio Pharmaceuticals had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 2 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.67 beat Inovio Pharmaceuticals' score of 0.75 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inovio Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics' return on equity of -81.92% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Summary

Inovio Pharmaceuticals beats Kyverna Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Entera Bio's return on equity of -147.19% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Entera Bio has higher earnings, but lower revenue than Inovio Pharmaceuticals. Entera Bio is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.35	N/A
Inovio Pharmaceuticals	$60K	2,154.17	-$84.95M	-$0.91	N/A

Entera Bio has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

In the previous week, Inovio Pharmaceuticals had 6 more articles in the media than Entera Bio. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat Inovio Pharmaceuticals' score of 0.75 indicating that Entera Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Entera Bio	Very Positive
Inovio Pharmaceuticals	Positive

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Entera Bio currently has a consensus target price of $9.00, indicating a potential upside of 216.90%. Inovio Pharmaceuticals has a consensus target price of $3.17, indicating a potential upside of 153.33%. Given Entera Bio's higher possible upside, analysts clearly believe Entera Bio is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Inovio Pharmaceuticals beats Entera Bio on 9 of the 15 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Prothena?

Prothena (NASDAQ:PRTA) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Inovio Pharmaceuticals has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	48.29	-$244.09M	-$0.84	N/A
Inovio Pharmaceuticals	$60K	2,154.17	-$84.95M	-$0.91	N/A

97.1% of Prothena shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Inovio Pharmaceuticals had 5 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Inovio Pharmaceuticals and 2 mentions for Prothena. Prothena's average media sentiment score of 1.27 beat Inovio Pharmaceuticals' score of 0.75 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inovio Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prothena presently has a consensus price target of $24.57, indicating a potential upside of 175.16%. Inovio Pharmaceuticals has a consensus price target of $3.17, indicating a potential upside of 153.33%. Given Prothena's higher probable upside, analysts clearly believe Prothena is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Prothena has a beta of -0.33, indicating that its stock price is 133% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Summary

Prothena beats Inovio Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Inovio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INO vs. The Competition

Export

Metric	Inovio Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$129.25M	$3.85B	$7.12B	$12.84B
Dividend Yield	N/A	3.63%	2.56%	10.57%
P/E Ratio	-1.37	14.18	273.26	25.18
Price / Sales	2,154.17	1,409.57	639.25	90.23
Price / Cash	N/A	106.61	77.33	51.83
Price / Book	3.47	15.12	10.33	6.20
Net Income	-$84.95M	-$22.82M	$3.49B	$358.38M
7 Day Performance	-12.59%	-4.31%	-3.29%	-2.35%
1 Month Performance	63.23%	0.39%	-0.26%	-2.61%
1 Year Performance	-52.83%	38.28%	17.32%	8.08%

Inovio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INO Inovio Pharmaceuticals	3.0597 of 5 stars	$1.25 -2.3%	$3.17 +153.3%	-51.5%	$129.25M	$60K	N/A	320	News Coverage
MRNA Moderna	2.0987 of 5 stars	$141.65 +2.7%	$80.53 -43.2%	+462.0%	$56.55B	$1.94B	N/A	4,700	Trending News Analyst Forecast
ZURA Zura Bio	3.4055 of 5 stars	$5.50 -3.8%	$17.00 +209.0%	+161.2%	$527.16M	N/A	N/A	3	News Coverage Positive News Gap Down
KYTX Kyverna Therapeutics	2.0957 of 5 stars	$8.34 -0.4%	$30.00 +259.9%	+82.8%	$515.50M	N/A	N/A	96	Positive News
ENTX Entera Bio	2.743 of 5 stars	$2.97 -2.1%	$9.00 +203.5%	+50.0%	$515.41M	$40K	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INO) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, ZURA, KYTX, ENTX, and PRTA

How does Inovio Pharmaceuticals compare to Moderna?

Summary

How does Inovio Pharmaceuticals compare to Zura Bio?

Summary

How does Inovio Pharmaceuticals compare to Kyverna Therapeutics?

Summary

How does Inovio Pharmaceuticals compare to Entera Bio?

Summary

How does Inovio Pharmaceuticals compare to Prothena?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, ZURA, KYTX, ENTX, and PRTA

How does Inovio Pharmaceuticals compare to Moderna?

Does the media favor INO or MRNA?

Do insiders & institutionals have more ownership in INO or MRNA?

Is INO or MRNA more profitable?

Do analysts prefer INO or MRNA?

Which has higher valuation and earnings, INO or MRNA?

Which has more volatility and risk, INO or MRNA?

Summary

How does Inovio Pharmaceuticals compare to Zura Bio?

Which has more risk & volatility, INO or ZURA?

Do analysts rate INO or ZURA?

Which has higher valuation & earnings, INO or ZURA?

Is INO or ZURA more profitable?

Do institutionals and insiders hold more shares of INO or ZURA?

Does the media prefer INO or ZURA?

Summary

How does Inovio Pharmaceuticals compare to Kyverna Therapeutics?

Do analysts recommend KYTX or INO?

Which has higher earnings & valuation, KYTX or INO?

Which has more risk and volatility, KYTX or INO?

Do institutionals and insiders hold more shares of KYTX or INO?

Does the media favor KYTX or INO?

Is KYTX or INO more profitable?

Summary

How does Inovio Pharmaceuticals compare to Entera Bio?

Is ENTX or INO more profitable?

Which has better earnings & valuation, ENTX or INO?

Which has more volatility & risk, ENTX or INO?

Does the media prefer ENTX or INO?

Do institutionals & insiders believe in ENTX or INO?

Do analysts recommend ENTX or INO?

Summary

How does Inovio Pharmaceuticals compare to Prothena?

Which has higher earnings & valuation, PRTA or INO?

Do institutionals & insiders have more ownership in PRTA or INO?

Does the media prefer PRTA or INO?

Do analysts prefer PRTA or INO?

Which has more risk & volatility, PRTA or INO?

Is PRTA or INO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools